Add-on activity
This activity includes patient counseling videos.
Program Description
Respiratory syncytial virus (RSV) commonly presents as an upper respiratory infection that can cause increased morbidity and mortality for older patients, especially for those with underlying comorbidities. The current treatment paradigm for RSV is limited and mostly supportive care, but several RSV vaccine candidates are under development in various stages of clinical trials. Pharmacists are in a unique position to identify patients with risk factors for more severe disease and ensure patients are familiar with tactics to reduce transmission of RSV. Pharmacists can provide education on the effectiveness of emerging RSV vaccines in preventing disease complications. Expert panelists will outline the pharmacist’s role in promoting acceptance of new vaccines and overcoming barriers associated with reduced vaccination coverage among some populations by addressing disparities in care. Included in this activity are patient counseling videos to illustrate the role of the pharmacist in educating patients about RSV and emerging vaccines.
Target audience: Health-system, retail, and specialty pharmacists
Type of activity: Application
Release date: July 19, 2022
Expiration date: September 19, 2022
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Determine the incidence, risk factors, and diagnostic criteria for respiratory syncytial virus (RSV) in older adults
- Examine the most current efficacy data for emerging RSV vaccines as well as administration, dosing, and potential adverse effects
- Identify the role of the pharmacist in educating patients about preventing RSV infections, including information about emerging vaccines for RSV
Stefan Gravenstein, MD, MPH
Moderator
David S. Greer Professor of Geriatric Medicine
Department of Medicine and Health Services Policy and Practice
Director, Division of Geriatrics and Palliative Medicine
Alpert Medical School of Brown University
Providence, Rhode Island
Spencer H. Durham, PharmD, BCPS, BCIDP
Associate Clinical Professor of Pharmacy Practice
Director, Alumni & Professional Affairs
Auburn University Harrison College of Pharmacy
Auburn, Alabama
Clinical Pharmacist Specialist, Infectious Diseases
Central Alabama Veterans Health Care System
Montgomery, Alabama
Barbara J. Zarowitz, PharmD, MSW, BCPS, BCGP, FCCP, FASCP
Senior Advisor, Peter Lamy Center on Drug Therapy and Aging
Affiliate Professor, University of Maryland School of Pharmacy
Baltimore, Maryland
Adam C. Welch, PharmD, MBA, FAPhA
Associate Professor, Pharmacy Practice
East Tennessee State University Bill Gatton College of Pharmacy
Johnson City, Tennessee
Brittany Hoffmann-Eubanks, PharmD, MBA
Medical Writer for Panel Discussion
Founder and CEO
Banner Medical LLC
Frankfort, Illinois
Rupal Mansukhani, PharmD, CTTS, FAPhA
Medical Writer for Patient Counseling Videos
Clinical Associate Professor
Ernest Mario School of Pharmacy, Rutgers University
Piscataway, New Jersey
Clinical Pharmacist
Morristown Medical Center
Morristown, New Jersey
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs) under the ACPE universal activity number 0290-0000-22-291-L06-P. The activity is available for CE credit through September 19, 2022.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Faculty Presenters
Spencer H. Durham, PharmD, BCPS, BCIDP, has the following financial relationship with a commercial interest to disclose:
Consultant: Shionogi Pharmaceuticals, Theratechnologies
Barbara J. Zarowitz, PharmD, MSW, BCPS, BCGP, FCCP, FASCP, has the following financial relationship with a commercial interest to disclose:
Grant/Research Support: NIA Grant Alzheimer Disease RO
Consultant: Akebia, Merck, Lilly
Educational Support: ASHP/ACCP for DOAC’s in Oldest Old
The following contributors have no relevant financial relationships with commercial interests to disclose:
Moderator
Stefan Gravenstein, MD, MPH
Faculty Presenter
Adam C. Welch, PharmD, MBA, FAPhA
Medical Writers
Brittany Hoffmann-Eubanks, PharmD, MBA, and Rupal Mansukhani, PharmD, CTTS, FAPhA
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Liza Patel, PharmD, RPh; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms